Evaluation of Ability of Biochemical Markers of Bone Turnover to Predict a Response to Increased Doses of HRT

Calcified Tissue International

Volumn 74, Issue 5, 2004, Pages 415-423

  Rosen, H N ^a,b,c   Parker, R A ^a   Greenspan, S L ^e   Iloputaife, I D ^c   Bookman, L ^a   Chapin, D ^a   Perlmutter, I ^a   Kessel, B ^a   Qvist, P ^d   Rosenblatt, M ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c RESEARCH AND TRAINING INSTITUTE   (United States)

^d Norkik Bioscience A/S   (Denmark)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biochemical markers of bone turnover; Bone density; Dose; Estrogen; Least significant change

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CITRATE CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE;

ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG MEGADOSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOLOGICAL TECHNIQUE; MAJOR CLINICAL STUDY; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE; STANDARD; UTERUS;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PEPTIDES;

EID: 2442561817     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-003-0114-5     Document Type: Article

References (38)

1. Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, et al. (1996) Bone density change and biochemical indices of skeletal turnover. Calcif Tissue Int 58:236-243
2. Greendale GA, Wells B, Marcus R, Barret-Connor E (2000) How many women lose BMD while taking hormone replacement therapy? Results from the PEPI trial. Arch Intern Med 160:3065-3071
3. Chetkowski R, Meldrum DR, Steingold KA, Randle D, Lu J, et al. (1986) Biologic effects of transdermal estradiol. N Engl J Med 314:1615-1620
4. Sugimoto AK, Hodsman AB, Nisker JA (1993) Long-term GNRH agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertil Steril 60:672-674
5. Genant H, Lucas J, Weiss S, Akin M, Emkey R, et al. (1997) Low-dose esterified estrogen therapy. Effects on bone, plasma estradiol concentrations, endometrium and lipid levels. Arch Intern Med 157:2609-2615
6. Cummings S, Palermo L, Browner W, Marcus R, Wallace R, et al. (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. FIT research group. JAMA 283:1318-1321
7. Maschak C, Lobo R, Dozono-Takano R, Eggena P, Nakamura R, et al. (1982) Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 144:511-518
8. Rosenqvist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, et al. (1998) Serum Crosslaps one-step-ELISA. First application of monocloncal antibodies for measurement in serum of bone-related degredation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281-2289
9. Clemens J, Herrick M, Singer F, Eyre D (1997) Evidence that serum NTX can act as an immunochemical marker of bone resorption. Clin Chem 43:2058-2063
10. Garnero P, Delmas PD (1993) Assessment of serum levels of bone alkaline phosphatase with a new IRMA in patients with metabolic bone disease. J Clin Endocrinol Metab 77:1046-1053
11. Garnero P, Weichung JS, Gineyts E (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal women in response to alendronate therapy. J Clin Endocrinol Metab 79:1693-1700
12. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, et al. (1998) Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 63:363-368
13. Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, et al. (2000) Biological variability of serum and urine N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 15:594-598
14. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, et al. (2000) Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low CV and large changes with bisphosphonate therapy. Calcif Tissue Int 66:100-103
15. Marcus R, Holloway L, Wells B, Greendale GA, James MK, et al. (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the PEPI trial. J Bone Miner Res 14:1583-1595
16. Miller PD, Baran DT, Bilzekian JP, Greenspan SL, Lindsay R, et al. (1999) Practical clinical application of biochemical markers of bone turnover. J Clin Densitom 2:323-342
17. Rogers A, Hannon R, Eastell R (2000) Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 15:1398-1404
18. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694-702
19. Christgau S, Rosenqvist C, Alexanderson P, Bjarnason N, Ravn P, et al. (1998) Clinical evaluation of the serum CrossLaps one-step ELISA, a new assay measuring the serum concentration of bone-dervied degradation products of type I collagen C-telopeptides. Clin Chem 44:2290-2300
20. Chestnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, et al. (1997) Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of BMD. Am J Med 102:29-37
21. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich R, et al. (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363-2368
22. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, et al. (1998) Early change in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 13:1431-1438
23. Greenspan SL, Rosen HN, Parker RA (2000) Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy. J Clin Endocrinol Metab 85:3537-3540
24. Chow J, Tobias J, Colston K (1992) Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J Clin Inves 89:74-78
25. Khastgir G, Studd J, Holland D (2001) Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporosis Int 12:465-470
26. Khastgir G, Studd S, Holland N (2001) Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study. J Clin Endocrinol Metab 86:289-295
27. Machado A, Hannon R, Eastell R (1999) Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14:602-608
28. Hannon R, Blumsohn A, Naylor K, Eastell R (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124-1133
29. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287:2668-2676
30. Writing group (1996) Effects of hormone therapy on bone mineral density. JAMA 276:1389-1396
31. Gallagher JC, Kable WT, Goldgar D (1991) Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 90:171-178
32. Hesley R, Shepard K, Jenkins D, Riggs B (1998) Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporosis Int 8:159-164
33. Komulainen M, Korger H, Tuppurainen M, Heikkinen A, Honkanen R, et al. (2000) Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporosis Int 11:211-218
34. Dresner-Pollak R, Mayer M, Hochner-Celiniker D (2000) The decrease in serum bone-specific alkaline phosphatase predicts BMD response to HRT in early postmenopausal women. Calcif Tissue Int 66:104-107
35. Yu W, Qin M, Xu L, Kuijk C Van, Meng X, et al. (1999) Normal changes in spine BMD in a Chinese population: assessment by QCT and DXA. Osteoporosis Int 9:179-187
36. Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS (2000) Posterior-anterior and lateral DXA for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res 15:1417-1424
37. Lindsay R, Hart D, Clark D (1984) The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63:759-763
38. Writing group(2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal resufts from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333